Ten years after MIDAS: icodextrin lights and shadows.
Amici
Gianpaolo
G
Nephrology and Dialysis Division, Regional Hospital S. Maria dei Battuti, Treviso, Italy. amicig@tin.it
Da Rin
Giorgio
G
Agostini
Adriano
A
Velo
Sonia
S
Bocci
Carlo
C
D001672:Biocompatible Materials / Q000009:adverse effects; D015314:Dialysis Solutions / Q000493:pharmacokinetics / Q000494:pharmacology*; D005260:Female; D005936:Glucans / Q000493:pharmacokinetics / Q000494:pharmacology*; D005947:Glucose / Q000493:pharmacokinetics / Q000494:pharmacology*; D006801:Humans; D000077607:Icodextrin; D007676:Kidney Failure, Chronic / Q000628:therapy; D008297:Male; D010530:Peritoneal Dialysis / Q000009:adverse effects / Q000379:methods*; D010531:Peritoneal Dialysis, Continuous Ambulatory / Q000009:adverse effects / Q000379:methods; D010538:Peritonitis / Q000517:prevention & control*; D011379:Prognosis; D016032:Randomized Controlled Trials as Topic; D012189:Retrospective Studies; D012449:Safety; D012680:Sensitivity and Specificity; D013997:Time Factors; D016896:Treatment Outcome
D001672:Biocompatible Materials; D015314:Dialysis Solutions; D005936:Glucans; D000077607:Icodextrin; D005947:Glucose